InterMune (ITMN) Is Today's Perilous Reversal Stock

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified InterMune ( ITMN) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified InterMune as such a stock due to the following factors:

  • ITMN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $148.9 million.
  • ITMN has traded 899,845 shares today.
  • ITMN is down 3.1% today.
  • ITMN was up 14.4% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in ITMN with the Ticky from Trade-Ideas. See the FREE profile for ITMN NOW at Trade-Ideas

More details on ITMN:

InterMune, Inc., a biotechnology company, focuses on the research, development, and commercialization of therapies for pulmonology and orphan fibrotic diseases in North America and Europe. Currently there are 7 analysts that rate InterMune a buy, 1 analyst rates it a sell, and 1 rates it a hold.

The average volume for InterMune has been 2.0 million shares per day over the past 30 days. InterMune has a market cap of $4.9 billion and is part of the health care sector and drugs industry. The stock has a beta of 3.61 and a short float of 15.8% with 3.24 days to cover. Shares are up 253.4% year-to-date as of the close of trading on Wednesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Week in Review: Trump Rally Fizzles but Stocks End 2016 With Big Gains

Post-Trump Rally Stalls as Dow Jones Slips Further From 20,000 Mark

Stocks Slump Continues With All S&P 500 Sectors in Negative Territory

Hacking Case Shows Mounting Risk for M&A Law Firms, Corporate Clients

Stocks Turn Negative, Prolonging Dow's Trek Toward 20,000